QSAR STUDY OF HCV NS5B POLYMERASE INHIBITORS USING THE GENETIC ALGORITHM-MULTIPLE LINEAR REGRESSION (GA-MLR)

被引:0
|
作者
Rafiei, Hamid [1 ]
Khanzadeh, Marziyeh [2 ]
Mozaffari, Shahla [2 ]
Bostanifar, Mohammad Hassan [1 ]
Avval, Zhila Mohajeri [2 ]
Aalizadeh, Reza [3 ]
Pourbasheer, Eslam [2 ]
机构
[1] Islamic Azad Univ, Dashtestan Branch, Dept Chem, Dashtestan, Iran
[2] PNU, Dept Chem, POB 19395-3697, Tehran, Iran
[3] Univ Athens, Dept Chem, Analyt Chem Lab, Athens 15771, Greece
来源
EXCLI JOURNAL | 2016年 / 15卷
关键词
QSAR; Genetic algorithms; Multiple linear regression; HCV; HEPATITIS-C; RNA-POLYMERASE; IDENTIFICATION; ANTAGONISTS; PREVENTION; PREDICTION; STRATEGY; THERAPY; INDEXES;
D O I
暂无
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Quantitative structure-activity relationship (QSAR) study has been employed for predicting the inhibitory activities of the Hepatitis C virus (HCV) NS5B polymerase inhibitors. A data set consisted of 72 compounds was selected, and then different types of molecular descriptors were calculated. The whole data set was split into a training set (80 % of the dataset) and a test set (20 % of the dataset) using principle component analysis. The stepwise (SW) and the genetic algorithm (GA) techniques were used as variable selection tools. Multiple linear regression method was then used to linearly correlate the selected descriptors with inhibitory activities. Several validation technique including leave-one-out and leave-group-out cross-validation, Y-randomization method were used to evaluate the internal capability of the derived models. The external prediction ability of the derived models was further analyzed using modified r(2), concordance correlation coefficient values and Golbraikh and Tropsha acceptable model criteria's. Based on the derived results (GA-MLR), some new insights toward molecular structural requirements for obtaining better inhibitory activity were obtained.
引用
收藏
页码:38 / 53
页数:16
相关论文
共 50 条
  • [21] Hepatitis C therapy with HCV NS5B polymerase inhibitors
    Soriano, Vincent
    Vispo, Eugenia
    de Mendoza, Carmen
    Labarga, Pablo
    Vicente Fernandez-Montero, Jose
    Poveda, Eva
    Trevino, Ana
    Barreiro, Pablo
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (09) : 1161 - 1170
  • [22] Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors
    Hendricks, Robert T.
    Fell, Jay B.
    Blake, James F.
    Fischer, John P.
    Robinson, John E.
    Spencer, Stacey R.
    Stengel, Peter J.
    Bernacki, April L.
    Leveque, Vincent J. P.
    Le Pogam, Sophie
    Rajyaguru, Sonal
    Najera, Isabel
    Josey, John A.
    Harris, Jason R.
    Swallow, Steven
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (13) : 3637 - 3641
  • [23] Quantitative structure and bioactivity relationship study on HCV NS5B polymerase inhibitors
    Wang, M.
    Zhong, M.
    Yan, A.
    Li, L.
    Yu, C.
    SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2014, 25 (01) : 1 - 15
  • [24] NS5B polymerase inhibitors in phase II clinical trials for HCV infection
    Borgia, Guglielmo
    Maraolo, Alberto Enrico
    Nappa, Salvatore
    Gentile, Ivan
    Buonomo, Antonio Riccardo
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (03) : 243 - 250
  • [25] QSAR study of Nav1.7 antagonists by multiple linear regression method based on genetic algorithm (GA–MLR)
    Eslam Pourbasheer
    Reza Aalizadeh
    Mohammad Reza Ganjali
    Parviz Norouzi
    Javad Shadmanesh
    Constantinos Methenitis
    Medicinal Chemistry Research, 2014, 23 : 2264 - 2276
  • [26] 3-Heterocyclyl quinolone inhibitors of the HCV NS5B polymerase
    Kumar, Dange V.
    Rai, Roopa
    Brameld, Ken A.
    Riggs, Jennifer
    Somoza, John R.
    Rajagopalan, Ravi
    Janc, James W.
    Xia, Yu M.
    Ton, Tony L.
    Hu, Huiyong
    Lehoux, Isabelle
    Ho, Joseph D.
    Young, Wendy B.
    Hart, Barry
    Green, Michael J.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (01) : 300 - 304
  • [27] Comparative QSAR Studies on the Novel Series of Thiazolones and Tetrazole Derivatives as HCV NS5B Polymerase Allosteric Inhibitors
    Singh, Shalini
    LETTERS IN DRUG DESIGN & DISCOVERY, 2009, 6 (04) : 286 - 297
  • [28] Synthesis and evaluation of Janus type nucleosides as potential HCV NS5B polymerase inhibitors
    Zhou, Longhu
    Amblard, Franck
    Zhang, Hongwang
    McBrayer, Tamara R.
    Detorio, Mervi A.
    Whitaker, Tony
    Coats, Steven J.
    Schinazi, Raymond F.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (11) : 3385 - 3388
  • [29] QSAR study of prolylcarboxypeptidase inhibitors by genetic algorithm: Multiple linear regressions
    Pourbasheer, Eslam
    Vahdani, Saadat
    Aalizadeh, Reza
    Banaei, Alireza
    Ganjali, Mohammad Reza
    JOURNAL OF CHEMICAL SCIENCES, 2015, 127 (07) : 1243 - 1251
  • [30] QSAR modeling of antimalarial activity of urea derivatives using genetic algorithm-multiple linear regressions
    Beheshti, Abolghasem
    Pourbasheer, Eslam
    Nekoei, Mehdi
    Vahdani, Saadat
    JOURNAL OF SAUDI CHEMICAL SOCIETY, 2016, 20 (03) : 282 - 290